Charles Ryan, MD: Bone-Targeted Therapy
Would you consider bone-targeted therapy for this patient, and why?
CASE: Metastatic Prostate Cancer (Part 2)
Mathew J is a 61 year old African American male who presented to his primary care physician with lower urinary tract symptoms, including sporadic hematuria. He complains of abdominal pain and low back pain starting four months ago and increasing in frequency. Prior medical history includes non-insulin dependent diabetes mellitus, well-controlled on metformin since 2006. The patient was referred to urology for further evaluation. ng/ml.
During his most recent follow-up exam, the patient complained of intermittent back pain and increasing fatigue.
- Digital rectum exam revealed nodular prostate /L
- Serum PSA level; 129 ng/ml
- Alkaline phosphatase, 258
- TRUS/prostate biopsy: 53 gram prostate, 12/12 cores (+), Gleason 4 + 5
- CT indicates blastic lesions to lumbar spine and pelvis
- Bone Scan positive for T/L spine, pelvis, right femur, scapula
- ECOG performance status, 1
Apalutamide Outperforms Enzalutamide in mCSPC Survival
November 8th 2024In an interview with Targeted Oncology, Neal Shore, MD, FACS, discussed the background, findings, and implications of a real-world study of enzalutamide and apalutamide in patients with metastatic castration-sensitive prostate cancer.
Read More
